Question? Call us
212-363-7500Expired
Lead Plaintiff Deadline
Oct 26, 2021
Choose your preferred way to stay informed of new case launches and settlement deadlines
(a) the quality and integrity of the scientific data supporting Cassava’s claims for simufilam’s, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava’s claims for simufilam’s efficacy were biased; and (c) as a result of the foregoing, Defendants’ positive statements during the Class Period about the Company’s business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.
In order to be eligible to join the SAVA class action lawsuit, you must have incurred a loss on shares of Cassava purchased during the class period listed above.
If you suffered a loss in Cassava during the relevant time frame or pursuant to the relevant offering(s), you have until October 26, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
TOP